Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Published:2024-07 Issue: Volume:213 Page:111758
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Popovic Djordje S.,Patoulias Dimitrios,Popovic Lazar S.,Karakasis Paschalis,Papanas Nikolaos,Mantzoros Christos S.

Publisher

Elsevier BV

Reference18 articles.

1. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity;Gallwitz;Front Endocrinol (Lausanne),2022

2. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies;Elashoff;Gastroenterology,2011

3. Body fatness associations with cancer: evidence from recent epidemiological studies and future directions;Larsson;Metabolism,2022

4. Obesity and cancer risk: emerging biological mechanisms and perspectives;Avgerinos;Metabolism,2019

5. The relationship between diabetes mellitus and cancers and its underlying mechanisms;Zhu;Front Endocrinol (Lausanne),2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP